SCHEMBL7013828

SCHEMBL7013828

CCc1cc2c(OCC(=O)OC)cccn2c1Cc1ccccc1-c1ccccc1

nearest known ligand 0.67

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
PLA2G1B P04054 17/20 0.67
PLA2G2A P14555 4/20 0.55
PLA2G2E Q9NZK7 3/20 0.55
PLA2G5 P39877 2/20 0.55
PLA2G10 O15496 1/20 0.54
PLA2G2F Q9BZM2 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8024688 0.91 PLA2G1B (0.57) PLA2G1BPLA2G2APLA2G2EPLA2G5PLA2G10
SCHEMBL8022769 0.91 PLA2G1B (0.66) PLA2G1BPLA2G2APLA2G2EPLA2G5PLA2G10
SCHEMBL7010713 0.87 PLA2G1B (0.64) PLA2G1BPLA2G2APLA2G2EPLA2G5PLA2G10
SCHEMBL7011531 0.87 PLA2G1B (0.64) PLA2G1BPLA2G2APLA2G2EPLA2G5PLA2G10
SCHEMBL7010592 0.86 PLA2G1B (0.61) PLA2G1BPLA2G2APLA2G2EPLA2G5PLA2G10
SCHEMBL7007813 0.85 PLA2G1B (0.66) PLA2G1B
SCHEMBL7009863 0.84 PLA2G1B (0.66) PLA2G1BPLA2G2APLA2G2EPLA2G5PLA2G10
SCHEMBL7010500 0.83 PLA2G1B (0.55) PLA2G1BPLA2G2APLA2G2EPLA2G5PLA2G10
SCHEMBL7015597 0.83 PLA2G1B (0.54) PLA2G1BPLA2G2APLA2G2EPLA2G5PLA2G10
SCHEMBL7015569 0.80 PLA2G1B (1.00) PLA2G1BPLA2G2APLA2G2EPLA2G5PLA2G10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0977566-A1 METHOD FOR THE TREATMENT OF STROKE USING N-HETEROCYCLIC GLYOXYLAMIDE COMPOUNDS SHIONOGI & CO., LTD. (JP) 2000-02-09 EP claimed
WO-1998047508-A1 METHOD FOR THE TREATMENT OF STROKE USING N-HETEROCYCLIC GLYOXYLAMIDE COMPOUNDS SHIONOGI & CO., LTD. (JP) 1998-10-29 WO claimed
US-6645976-B1 Nonpancreatic secretory phospholipase (sPLA2) supressors such as 2-(3-Benzyl-8-hydroxy-2-ethylindolizin-1-yl)acetamide, administered to control release of fatty acid and prevent the arachidonic acid cascade; septic shock ELI LILLY AND COMPANY 2003-11-11 US disclosed
EP-0772596-B1 INDOLIZINE sPLA2 INHIBITORS LILLY CO ELI (US) 2003-10-01 EP disclosed
EP-1037630-A2 METHOD FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH APOPTOSIS USING N-HETEROCYCLIC GLYOXYLAMIDE COMPOUNDS SHIONOGI & CO., LTD. (JP) 2000-09-27 EP disclosed
EP-0977566-A1 METHOD FOR THE TREATMENT OF STROKE USING N-HETEROCYCLIC GLYOXYLAMIDE COMPOUNDS SHIONOGI & CO., LTD. (JP) 2000-02-09 EP disclosed
WO-1999024026-A2 METHOD FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH APOPTOSIS USING N-HETEROCYCLIC GLYOXYLAMIDE COMPOUNDS SHIONOGI & CO., LTD. (JP) 1999-05-20 WO disclosed
EP-0772596-A4 INDOLIZINE sPLA2 INHIBITORS LILLY CO ELI (US) 1999-01-13 EP disclosed
WO-1998047508-A1 METHOD FOR THE TREATMENT OF STROKE USING N-HETEROCYCLIC GLYOXYLAMIDE COMPOUNDS SHIONOGI & CO., LTD. (JP) 1998-10-29 WO disclosed
EP-0772596-A1 INDOLIZINE sPLA2 INHIBITORS ELI LILLY AND COMPANY (US) 1997-05-14 EP disclosed
WO-1996003383-A1 INDOLIZINE sPLA2 INHIBITORS ELI LILLY AND COMPANY (US) 1996-02-08 WO disclosed